Skip to main content
Return to CellCompass

Patient-Centric
CAR-T Cell Therapy Discussions

Peer-to-Peer Small Group Discussions

A CAR-T medical expert will moderate the small group discussion and offer insights and learnings from real-world experiences. You will be able to engage with your peers to enhance your understanding of the key determinants of CAR-T efficacy optimization and discuss best practices in caring for patients receiving CAR-T therapy.

Global CAR-T Experts

Sign up for a session and connect with a CAR-T expert

Previous Sessions:

FL

Real-World Experience with CAR-T in FL
Prof. Roch Houot profile photo

Prof. Roch Houot, MD, PhD

Head of Hematology Department, University Hospital of Rennes

Prof. Houot is the head of the Hematology Department at the University Hospital of Rennes in France. His main research interest is novel drug development and immunotherapy (including checkpoint inhibitors, bispecific antibodies, and CAR T-cells) for the treatment of lymphoid malignancies. He continues his work and dedication to investigating CAR T-cells and other innovative gene therapies in oncology.

pALL

The Role of Treatment Monitoring and MRD Assessment After CAR-T Cell Infusion
Sara Ghorashian profile photo

Sara Ghorashian, MD, PhD

Hematologist, University College London Institute of Child Health

Dr. Ghorashian is a leader in cell therapy research at the University College London Institute of Child Health. She has clinical interests in pediatric malignant hematology and is a co-investigator on two CAR-T cell studies for ALL. She works to improve outcomes with children with high risk or relapsed hematologic malignancies.

Identification of Appropriate Patients for CAR-T Cell Therapy
Prof. Peter Bader profile photo

Prof. Peter Bader, MD

Professor of Pediatrics, Johann Wolfgang Goethe University; Head, Stem Cell Transplantation and Immunology, University Hospital, Germany

From 2014 to 2018 Prof. Bader was chairman of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). In March 2019 he was Co-President of the 45th Annual EBMT Meeting in Frankfurt. His research is focused in particular on preemptive strategies to prevent relapse after allogeneic stem cell transplantation in children and adolescents with malignant diseases as well as the development and application of innovative cell therapy.

The Role of Stem-cell Transplant in the CAR-T Cell Therapy Era
Sara Ghorashian profile photo

Sara Ghorashian, MD, PhD

Hematologist, University College London Institute of Child Health, United Kingdom

Dr. Ghorashian is a leader in cell therapy research at the University College London Institute of Child Health. She has clinical interests in pediatric malignant hematology and is a co-investigator on two CAR-T cell studies for ALL. She works to improve outcomes with children with high risk or relapsed hematologic malignancies.

DLBCL

Bridging Therapy, Focusing on the Use of Pola-BR (Efficacy and AE)
Satoshi Yoshihara profile photo

Satoshi Yoshihara, MD

Associate Professor, Hyogo College of Medicine, Japan

Dr. Yoshihara has broad experience in real-world treatment of patients with CAR-T therapy for lymphoma, ALL, and myeloma. He is particularly interested in investigating approaches aimed to improve real-world CAR-T Therapy outcomes by enhancing T-cell collection efficiency, optimizing bridging therapy, and management of adverse events.

Potential Way to Improve Existing/Approved CAR-T Cell Therapy by In Vivo Immunomodulation
Antonia Müller profile photo

Antonia Müller, MD

Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna, Austria

Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.

Role of Bone-marrow Assessment Before and After CAR-T Infusion
Antonia Müller profile photo

Antonia Müller, MD

Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna, Austria

Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.

Radiation Prior to CAR-T Infusion – a Promising Bridging Strategy to Optimize Outcomes
Ulf Schnetzke profile photo

Ulf Schnetzke, MD

Senior Physician, Jena University Hospital, Germany

Dr. Ulf Schnetzke is a senior physician in the Department of Hematology and Internal Oncology. He has an interest in lymphomas and optimizing patient outcomes with CAR-T cell therapy.

Additional sessions coming soon

*Designates mandatory field

First Name is a required field!
Last Name is a required field!
Email is a required field!
Please provide the email address to your affiliated hospital, e.g. elise@pennhospital.com.
Affiliated Hospital is a required field!
Job Title is a required field!
Specialty is a required field!
Country is a required field!
Please select at least one session!
You must accept this agreement.

*Designates mandatory field

This is a paid promotion by Novartis. By registering for this event, you agree that your personal data will be processed in accordance with the Novartis Privacy Policy.

This site is intended for global professionals only